Mumbai: Pharma major Lupin Limited (Lupin) announced today the successful completion of a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Goa manufacturing facility without any observations. The inspection which started on Monday, July 17^th concluded today afternoon. 

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 4^th and the 6^th largest generics pharmaceutical company by market capitalization and revenues globally (March 31^st, 2017, Bloomberg). The Company is the 4^th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); the 2^nd largest Indian pharmaceutical company by global revenues; the 6^th largest generic pharmaceutical player in Japan and the 6^th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT March 2017).

For the financial year ended 31^st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com  for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –
Pooja Thakran
VP – Corporate Communications
Ph: +91-22-66402531 / 9811665000
Email: poojathakran@lupin.com

or

Arvind Bothra
Head – Investor Relations and M&A
Ph: +91-22-66402137
Email: arvindbothra@lupin.com